Publications by authors named "Matthias Geberth"

Claim this Profile
C
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Matthias Geberth

Breast· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W Beckmann, Erik Belleville, Matthias Geberth

Breast· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Michael P Lux, Naiba Nabieva, Andreas D Hartkopf, Jens Huober, Bernhard Volz, Matthias Geberth

Cancers (Basel)· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Andreas D Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Matthias Geberth

Breast· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Andreas Schneeweiss, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth

Anticancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
J Thaddeus Beck, Gabriel N Hortobagyi, Mario Campone, Fabienne Lebrun, Ines Deleu, Matthias Geberth

Breast Cancer Res Treat· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical management of everolimus-related toxicities in patients with advanced solid tumors.
Viktor Grünwald, Steffen Weikert, Marianne E Pavel, Dieter Hörsch, Diana Lüftner, Matthias Geberth

Onkologie· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Michael Gnant, Jose Baselga, Hope S Rugo, Shinzaburo Noguchi, Howard A Burris, Matthias Geberth

J Natl Cancer Inst· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.
Manfred Kaufmann, Erika Graf, Walter Jonat, Wolfgang Eiermann, Sabine Vescia, Matthias Geberth

Eur J Cancer· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
Gunter von Minckwitz, Erika Graf, Matthias Geberth, Wolfgang Eiermann, Walter Jonat

Eur J Cancer· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Manfred Kaufmann, Erika Graf, Walter Jonat, Wolfgang Eiermann, Matthias Geberth

J Clin Oncol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy.
Andreas Schneeweiss, Julia Katretchko, Hans-Peter Sinn, Kristina Unnebrink, Christian Rudlowski, Matthias Geberth

Anticancer Drugs· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis